Question-and-Answer Session
Operator
(Operator Instruction) Thank you our first question is coming from Matt Dolan of Roth Capital. Please go ahead.
Matt Dolan - Roth Capital
Hi guys. Good morning.
Richard Satin
Hi, Matt. Good morning, Matt.
Matt Dolan - Roth Capital
Just couple of question first Richard can you break out the growths in a operating margin experience between Medegen and like we see MDCI business and give Paul your comments on the inefficiencies in the near terms may be help us in terms of growth margin.
Were there are any product mix of coming an impact here in the September quarter how should we look at were we stand and they are going forward.
Richard Satin
I think that if you look at the margins on the Medical Action businesses, that clearly business as usual. And on the Medegen the gross margins will negatively impacted as result for those manufacturing inefficiencies.
If we didn’t incur those which, we don’t have a crystal ball but obviously the margins would have been very close to were they were historically as a combined into this since we acquired Medegen and overall there margins remains exactly were we thought they would be, other than you the head counter we had as a result of the consolidation.
Paul Meringolo
Hi, Matt. Again to a larger extent the Medegens margin's clearly were impacted by this million dollars its clear, as about they are for a medical action side there is a lot of pluses and minuses that have happened over the last three months.
But I would say that the cost impacts that we had from a China side and obviously from a resins side have absolutely put some pressure on margins there. And that’s why we are focused on making sure that we execute a price increase to the marketplace.
And as you know, from previous conference calls and previous price increases we’ve had, from the time they announced, to the time they hit the P&L there’s a big lag there. And it’s a complex process and it happens in pieces.
But you’ve seeing in the past that we had the ability to raise prices keep our sales numbers and stop the bleeding from a core side. And so we expect that trend to continue going forward from here.
Matt Dolan - Roth Capital
And in terms of timing on that price increase and magnitude?
- To read the full transcript on Seeking Alpha, click here »
